This email address is being protected from spambots. You need JavaScript enabled to view it., Scientific Coordinator

Dept Clinical Pharmacology

Centre Hospitalo-Universitaire de la Pitié-Salpêtrière

47, Bd de l’Hôpital

75013 Paris (France)

Tel : +33 1 42 16 16 69

 

This email address is being protected from spambots. You need JavaScript enabled to view it., Scientific co-Coordinator

Brighton and Sussex Medical School

Trafford Centre for Biomedical Research

University of Sussex, Falmer

East Sussex BN1 9RY (UK)

Tel: +44 (0)1273 87 73 57

Fax: +44 (0)1273 87 29 41

News

Rare disease Day 2021 – 28 February 2021

Rare Disease Day takes place on the last day of February each year. The main objective of Rare Disease Day is to raise awareness amongst the general public and decision-makers about rare diseases such as ALS and their impact on patients' lives.

Take a look at the events happening around the world for rare disease day: https://www.rarediseaseday.org/

Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial

Results in this paper reveal that low dose IL-2 significantly increased the numbers of circulating Tregs, as predicted, and – importantly – improved their ability to control other immune cell responses that contribute to nerve cell damage.

Further information can be found at MND Research Blog

End of trial recruitment phase this autumn

The MIROCALS (Modifying Immune Response and Outcomes in ALS) Clinical Trial is still on-going, with recruitment continuing until the end of September 2019.

Read more
europe

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No. 633413.